Multicenter, prospective, open-label, observational study of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension

Clinical Ophthalmology, 05/14/2012

Bimatoprost 0.01% can produce additional intraocular pressure (IOP)–lowering effects when used in routine clinical practice in patients who have received prior therapy, in addition to lowering IOP in previously untreated patients. A high rate of continuation of therapy with bimatoprost 0.01% was observed in patients who switched from a variety of different medications. The results suggest that bimatoprost 0.01% is a suitable first–choice therapy in patients with primary open–angle glaucoma or ocular hypertension.

Print Article Summary Cat 2 CME Report